Terminated PHASE2 INTERVENTIONAL 1-arm NCT01382745

Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers

A Phase II Clinical Study Using Nimotuzumab in Combination With External Beam Radiation Therapy in the Treatment of Patients With Carcinomas of the Anal Canal

Sponsor: Dr. Te Vuong

Conditions Squamous Cell Carcinoma of Anal Canal

Interventions Intensity Modulated Radiation Therapy (IMRT) Nimotuzumab

Updated 5 times since 2017 Last updated: Jan 25, 2013 Started: Jan 31, 2012 Primary completion: Sep 30, 2021 Completion: Jan 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

low recruitment

This PHASE2 trial investigates Squamous Cell Carcinoma of Anal Canal and is currently terminated or withdrawn. Dr. Te Vuong leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dr. Te Vuong
YM BioSciences

Data source: Sir Mortimer B. Davis - Jewish General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada